What if solving brain games and puzzles on a computer could reduce the chances of developing dementia such as Alzheimer’s or delay the debilitating loss of function associated with the disease? That’s the question researchers from the University of South...
Learn how to navigate the clinical research industry as it undergoes major shifts. Join the Vice President of Product Marketing at Medrio to learn how the industry is changing and how organizations can thrive through it all. In this live webinar, Leslie Olsen, Vice...
CStone Pharmaceuticals (CStone) today announced that the National Medical Products Administration (NMPA) recently approved the clinical trial application (CTA) to start a Phase I clinical trial in China for BLU-554 (CS3008), an inhibitor of fibroblast growth factor...
Major NIH-funded clinical trial adds nuanced evidence linking brain and vascular health Intensive lowering of blood pressure did not significantly reduce dementia risk but did have a measurable impact on mild cognitive impairment (MCI), according to the final,...
-Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), (the “Company”) a leading developer of RNA interference (RNAi) therapeutics, today announced the dosing of the first human volunteer in its Phase 1 clinical trial of DCR-HBVS, the Company’s investigational GalXCTM-based...
Email
Text